Details
Stereochemistry | ACHIRAL |
Molecular Formula | C32H55N4O |
Molecular Weight | 511.8053 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2
InChI
InChIKey=IOYZYMQFUSNATM-UHFFFAOYSA-N
InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1
Thonzonium Bromide is a cationic surface-active compound. As an additive to pharmacologic formulations, thonzonium bromide causes dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. Thonzonium
bromide is a component of FDA-approved Coly-Mycin S Otic, used for treating infections of the ear caused by certain bacteria. It has being shown that Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo, suggesting that Thonzonium bromide might be a useful alternative therapy in preventing or treating osteolytic diseases..
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0036035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26906912 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | COLY-MYCIN S Approved UseCortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. Launch Date1962 |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26906912
Mice: 5 mg/kg body weight, subcutaneous injection
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26906912
Mature osteoclasts (OCs) exposed to Thonzonium (100 or 200 nM) for 48 h demonstrated
attenuated capacity to resorb bone (reduction of 30% and
80% respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8048232
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
Z05ZE98FV8
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
237058
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
5456
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
DB09552
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
4605
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
25466-36-8
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
Z05ZE98FV8
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY | |||
|
Thonzonium
Created by
admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)